FDA Approves Bavencio (Avelumab) for Bladder Cancer



The US Food and Drug Administration (FDA) has approved the immunotherapy drug Bavencio (avelumab) to treat people with advanced urothelial carcinoma, the most common type of bladder cancer.



Source link

Comments are closed.